It is well known that some patients with depression will fail to respond to medications, but clinici...

Although cognitive-behavioral therapy for insomnia (CBT-I) is recommended as a first-line treatment ...

The Food and Drug Administration on Tuesday announced that a new warning of the serious adverse outc...

A study published today in JAMA Internal Medicine suggests that phone-based cognitive-behavioral the...

A form of cognitive-behavioral therapy especially developed to treat insomnia (CBT-I) was found to b...

A new surveillance study has found that benzodiazepine usage increases with age, with nearly 9 perce...

Last week, the Food and Drug Administration (FDA) approved Belsomra (suvoraxant) to treat individual...

The Food and Drug Administration has advised Merck Pharmaceuticals that suvorexant, the company’s in...

A Food and Drug Administration (FDA) advisory committee has decided that Merck's experimental drug s...